Sangamo Therapeutics (SGMO) Reports Q4 Loss, Misses Revenue Estimates
Portfolio Pulse from
Sangamo Therapeutics (SGMO) reported a Q4 loss of $0.11 per share, missing the Zacks Consensus Estimate of a $0.09 loss. This is an improvement from the $0.34 loss per share a year ago.
March 17, 2025 | 10:30 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Sangamo Therapeutics reported a Q4 loss of $0.11 per share, missing the expected $0.09 loss. Despite missing estimates, the loss is smaller than last year's $0.34 per share.
The earnings report shows a loss greater than expected, which is typically negative for stock prices. However, the improvement from last year's loss may mitigate some negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100